Roberto Pinto

Roberto Pinto

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2013 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
JRJosé Francisco Rocha
José Francisco Rocha
LALuis Almeida
Luis Almeida
AFAmílcar Falcão
Amílcar Falcão
PPP. Nuno Palma
P. Nuno Palma
ALAna I. Loureiro
Ana I. Loureiro
PSPatrício Soares‐Da‐Silva
Patrício Soares‐Da‐Silva
Aims: The aim of this study was to assess the tolerability, pharmacokinetics and inhibitory effect on erythrocyte soluble catechol‐O‐methyltransferase (S‐COMT) activity following repeated doses of opicapone.Methods: This randomized, placebo‐controlled, double‐blind study enrolled healthy male subjects who received either once daily placebo or opicapone 5, 10, 20 or 30 mg for 8 days.Results: Opicapone was well tolerated. Its systemic exposure increased in an approximately dose‐proportional manner with an apparent terminal half‐life of 1.0 to 1.4 h. Sulphation was the main metabolic pathway. Opicapone metabolites recovered in urine accounted for less than 3% of the amount of opicapone administered suggesting that bile is likely the main route of excretion. Maximum S‐COMT inhibition (Emax) ranged from 69.9% to 98.0% following the last dose of opicapone. The opicapone‐induced S‐COMT inhibition showed a half‐life in excess of 100 h, which was dose‐independent and much longer than plasma drug exposure. Such a half‐life translates into a putative underlying rate constant that is comparable with the estimated dissociation rate constant of the COMT–opicapone complex.Conclusion: Despite its short elimination half‐life, opicapone markedly and sustainably inhibited erythrocyte S‐COMT activity making it suitable for a once daily regimen.

18 December 2012 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
LALuis Almeida
Luis Almeida
JRJosé Francisco Rocha
José Francisco Rocha
AFAmílcar Falcão
Amílcar Falcão
PPP. Nuno Palma
P. Nuno Palma
ALAna I. Loureiro
Ana I. Loureiro
PSPatrício Soares-Da-Silva
Patrício Soares-Da-Silva

14 June 2014 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
JRJosé-Francisco Rocha
José-Francisco Rocha
AFAmílcar Falcão
Amílcar Falcão
ASAna Santos
Ana Santos
RPRoberto Pinto
Roberto Pinto
NLNelson Lopes
Nelson Lopes
PSPatrício Soares-Da-Silva
Patrício Soares-Da-Silva

4 February 2015 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
JFJ. J. Ferreira
J. J. Ferreira
JRJ.‐F. Rocha
J.‐F. Rocha
AFAmílcar Falcão
Amílcar Falcão
ASA. Santos
A. Santos
RPRoberto Pinto
Roberto Pinto
PSP. Soares‐Da‐Silva
P. Soares‐Da‐Silva

6 August 2015 in Clinical Pharmacology in Drug Development
Verified
Journal Article
Closed access
PDF file
JRJosé‐Francisco Rocha
José‐Francisco Rocha
Joaquim FerreiraJoaquim Ferreira
Joaquim Ferreira
AFAmílcar Falcão
Amílcar Falcão
ASAna Santos
Ana Santos
RPRoberto Pinto
Roberto Pinto
PSPatrício Soares‐Da‐Silva
Patrício Soares‐Da‐Silva

1 September 2013 in Epilepsy Research
Verified
Journal Article
Closed access
AFAmílcar Falcão
Amílcar Falcão
RPRoberto Pinto
Roberto Pinto
TNTeresa Nunes
Teresa Nunes
PSPatrício Soares-Da-Silva
Patrício Soares-Da-Silva